🇺🇸 LLY — Eli Lilly and Company

Healthcare Compra
← Volver

Precio actual

1.149,36 USD

Máx. histórico

1.292,65

16 días

Split 2:1 del 16/10/1997

Caída desde máximo

-11,08%

Rango 52 semanas

712,05 – 1.292,65

Variación hoy

-0,88%

Cierre anterior

1.159,60

Rango de hoy

1.138,31 – 1.158,43

Volumen hoy

2.159.931

Información
Nombre completo
Eli Lilly and Company
Divisa
USD
Mercado
NYSE
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
50.000
PER ⓘ
38,61 (puede no estar actualizado)
Dividend yield
0,60% (puede no estar actualizado)
Precio objetivo analistas
1.315,56 USD (puede no estar actualizado)
Primera cotización
01/06/1972
Precio actualizado
hace 3 días
Sobre la empresa

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Dividendos repartidos Total últimos 12 meses: 6,6900 USD · Yield: 0,58%
Fecha de pago Importe por participación
14/02/2019 0,6450 USD
14/11/2018 0,5630 USD
14/08/2018 0,5630 USD
16/05/2018 0,5630 USD
14/02/2018 0,5630 USD
14/11/2017 0,5200 USD
11/08/2017 0,5200 USD
11/05/2017 0,5200 USD
13/02/2017 0,5200 USD
10/11/2016 0,5100 USD
11/08/2016 0,5100 USD
11/05/2016 0,5100 USD
10/02/2016 0,5100 USD
10/11/2015 0,5000 USD
12/08/2015 0,5000 USD
Splits Registrados en el histórico de precios
Fecha Ratio
16/10/1997 2:1
21/12/1995 2:1
01/05/1989 2:1
30/01/1986 2:1
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
16/10/2013 48,94 49,01 48,51 48,91 +0,20% 1,02% 7.249.600
15/10/2013 48,80 49,08 48,60 48,81 -0,45% 0,98% 4.968.700
14/10/2013 48,63 49,05 48,47 49,03 +0,31% 1,19% 5.516.000
11/10/2013 48,63 49,09 48,51 48,88 -0,55% 1,19% 6.571.900
10/10/2013 48,82 49,16 48,51 49,15 +2,48% 1,33% 6.285.000
09/10/2013 48,09 48,26 47,53 47,96 -0,19% 1,52% 6.925.000
08/10/2013 47,75 48,36 47,53 48,05 +0,84% 1,74% 10.496.100
07/10/2013 48,17 48,21 47,56 47,65 -1,51% 1,35% 7.826.100
04/10/2013 48,86 48,86 48,01 48,38 -0,86% 1,74% 10.750.400
03/10/2013 50,25 50,29 48,50 48,80 -3,44% 3,56% 15.000.900
02/10/2013 50,45 50,67 50,22 50,54 -0,26% 0,89% 3.424.800
01/10/2013 50,41 50,69 50,24 50,67 +0,68% 0,89% 3.978.100
30/09/2013 50,30 50,66 50,21 50,33 -0,34% 0,89% 4.803.500
27/09/2013 50,68 50,82 50,07 50,50 -1,06% 1,48% 5.866.600
26/09/2013 51,20 51,95 50,15 51,04 -2,98% 3,52% 14.551.200
25/09/2013 52,60 52,95 52,36 52,61 +0,34% 1,12% 4.167.600
24/09/2013 52,99 53,09 52,33 52,43 -1,15% 1,43% 5.359.100
23/09/2013 53,84 53,86 52,83 53,04 -1,65% 1,91% 4.571.400
20/09/2013 54,04 54,18 53,72 53,93 +0,13% 0,85% 5.877.800
19/09/2013 53,90 54,12 53,63 53,86 -0,55% 0,91% 3.410.300
18/09/2013 53,87 54,25 53,22 54,16 +0,61% 1,91% 3.332.500
17/09/2013 53,64 54,18 53,61 53,83 +0,35% 1,06% 3.782.200
16/09/2013 53,77 53,84 53,43 53,64 +0,69% 0,76% 2.666.100
13/09/2013 53,01 53,29 52,93 53,27 +0,68% 0,68% 2.784.500
12/09/2013 52,90 53,22 52,76 52,91 +0,21% 0,87% 3.094.200
11/09/2013 52,87 53,15 52,69 52,80 -0,13% 0,87% 3.943.800
10/09/2013 52,89 53,13 52,53 52,87 +0,63% 1,13% 3.414.600
09/09/2013 52,41 52,58 52,09 52,54 +0,25% 0,93% 2.324.500
06/09/2013 52,22 52,73 51,69 52,41 +0,38% 1,99% 2.886.500
05/09/2013 52,29 52,35 51,92 52,21 +0,06% 0,82% 2.424.400